Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Apatinib in first-line maintenance of advanced gastric cancer
NCT03255811Unknown
- Sponsor
- Dongma Biotechnology
- Start
- Mar 2017
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of Rivoceranib in gastric cancer (GC) and gastroesophageal junction adenocarcinoma, sponsored by Dongma Biotechnology. Primary endpoint: Progression-Free Survival at 2 years. Status: unknown.
02
Drugs
Rivoceranib
03
Conditions
gastric cancer (GC)gastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT03255811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03255811.